Search Results

June 2022 "CRN04894 Selected for Oral Presentation SAN DIEGO, June 8, 2022 — Crinetics Pharmaceuticals Crinetics recently reported that administration of CRN04894 reduced both serum cortisol levels and 24

April 2022 "SAN DIEGO, April 12, 2022 — Crinetics Pharmaceuticals, Inc. All of the shares to be sold in the offering are to be sold by Crinetics. The gross proceeds to Crinetics from the offering, before deducting the underwriting discounts and commissions

Industry insights:  Crinetics' Palsonify gains momentum in acromegaly, a key indicator for pipeline expansion

December 2021 Crinetics Pharmaceuticals announced the formation of an independently operated new company nonpeptide radiopharmaceuticals for the treatment of a broad range of oncology indications "– Co-founded by Crinetics Company Launches with $30M in Initial Financing Provided by 5AM and Frazier – Pipeline is Built from Crinetics Nonpeptide Platform and Includes Drug Candidates and Leads Against 10 Oncology Targets – Radionetics and Crinetics to Collaborate on Multiple Additional targets SAN DIEGO, October 18, 2021 — Crinetics Pharmaceuticals

March 2022 Crinetics Pharmaceuticals Expands Executive Team With Appointment Of James Hassard As Chief Commercial Officer "SAN DIEGO – March 1, 2022 – Crinetics Pharmaceuticals, Inc.

Matchmaker, I recently had the pleasure of speaking with Beth Fleck, Director of In Vitro Pharmacology at Crinetics Mark:  “Beth, why did you decide to join Crinetics?” Beth:  “I was invited to join Crinetics a few years ago by some former colleagues and their description Crinetics hires people with big brains and small egos.” There are a lot of learning opportunities at Crinetics.  We collaborate and cross-pollenate a lot.”

insights into the 5-HT2C receptor as a therapeutic target for substance use disorders Industry News Crinetics Secondary Endpoints In The Phase 3 Pathfndr-1 Study Evaluating Treatment Of Patients With Acromegaly Crinetics - 4, 2024 | Chemotactic Cytokines GPCR Jobs NEW Senior Research Associate, In Vitro Pharmacology - Crinetics

Exhibition June 2 - 4, 2024 | Chemotactic Cytokines GPCR Jobs NEW Senior Scientist, In vitro pharmacology - Crinetics Pharmaceuticals NEW Senior Director, In vitro pharmacology - Crinetics Pharmaceuticals In vivo Antibody

Cytokines GPCR Jobs NEW Head of Human Resource Business Partners Senior Scientist, In vitro pharmacology - Crinetics Pharmaceuticals Senior Director, In vitro pharmacology - Crinetics Pharmaceuticals In vivo Antibody

Octant Apprentice Head of Human Resource Business Partners Senior Scientist, In vitro pharmacology - Crinetics Pharmaceuticals Senior Director, In vitro pharmacology - Crinetics Pharmaceuticals In vivo Antibody

Cytokines GPCR Jobs Head of Human Resource Business Partners Senior Scientist, In vitro pharmacology - Crinetics Pharmaceuticals Senior Director, In vitro pharmacology - Crinetics Pharmaceuticals In vivo Antibody

Capsule to Tablet PK Study for its Oral Non-Peptide Small Molecule GLP-1 Receptor Agonist GSBR-1290 Crinetics President of Medical Affairs Septerna to Participate in the Jefferies Global Healthcare Conference Crinetics

Octant Apprentice Head of Human Resource Business Partners Senior Scientist, In vitro pharmacology - Crinetics Pharmaceuticals Senior Director, In vitro pharmacology - Crinetics Pharmaceuticals Explore Dr.

Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1117567 in Healthy Adults Crinetics Business Update Nxera Pharma Operational Highlights and Consolidated Results for the First Quarter 2024 Crinetics

Development Expertise in Oncology Octant Bio will be at the Goldman Sachs Global Healthcare Conference Crinetics

accessed this week  across four critical domains: Industry insights:  Neurocrine at Morgan Stanley; Crinetics

Poon to Board of Directors Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing

Commercialization of Voyager’s GBA1 Program and Other Next-Generation Gene Therapies for Neurological Diseases Crinetics

GSK of HTL0027477, a Clinic-ready, First-in-Class Oral GPR35 Agonist for Inflammatory Bowel Disease Crinetics

Property for Its Series of Treg Depleting anti-CCR8 Antibodies, Including Best-in-class Candidate DT-7012 Crinetics

Jack Antel to its clinical advisory board Crinetics Pharmaceuticals First Quarter 2023 Earnings: Revenues

microscopy Structural analysis of the human C5a-C5aR1 complex using cryo-electron microscopy Industry News Crinetics

Epilepsy Phase 2 Study Part 1 IPO Raises $161M for GPCR-Based Drug Developer Structure Therapeutics Crinetics

with oral immunotherapy drug Trevena Reports Second Quarter 2023 Results and Provides Business Update Crinetics

Biotech Expands Global Intellectual Property Portfolio with Granted Patents in Australia and Singapore Crinetics

recently discussed this exciting opportunity with Beth Fleck, Director of In Vitro Pharmacology at Crinetics

Development and Reports Financing Highlights Neurocrine Biosciences Provides Development Pipeline Update Crinetics

Side Effects Driving Pharma Innovation in Oncology: Domain Therapeutics' Success Proven by Science Crinetics

Raises £3.5M ($4.6M) to Advance Generative AI Antibody Design Platform GPCR Safety Panels Launched Crinetics

raising $50M, spinning GPR68 small molecules into GIO New treatments being developed for schizophrenia Crinetics